Dose-dependent effect of flouxetine on 6-OHDA-induced catalepsy in male rats: A possible involvement of 5-HT1A receptors

Advanced Pharmaceutical Bulletin

Volumn 3, Issue 1, 2013, Pages 203-206

  Sharifi, Hamdolah ^a   Nayebi, Alireza Mohajjel ^b   Farajnia, Safar ^b  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b UNIVERSITY OF TABRIZ   (Iran)

Author keywords

6 Hydroxydopamine; Catalepsy; Fluoxetine; Rat

Indexed keywords

1 (2 METHOXYPHENYL) 4 (4 PHTHALIMIDOBUTYL)PIPERAZINE; FLUOXETINE; SEROTONIN 1A RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CATALEPSY; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; LOW DRUG DOSE; MALE; NONHUMAN; OUTCOME ASSESSMENT; RAT; SUBSTANTIA NIGRA PARS COMPACTA; TREATMENT DURATION;

EID: 84874964140     PISSN: 22285881     EISSN: 22517308     Source Type: Journal    
DOI: 10.5681/apb.2013.033     Document Type: Article

References (23)

1. Singh N, Pillay V, Choonara YE. Advances in the treatment of Parkinson's disease Prog Neurobiol 2007;81:29-44.
2. Di Filippoa M, Chiasserini D, Tozzi A, Picconi B, Calabresi P. Mitochondria and the link between neuroinflammation and neurodegeneration. J Alzheimers Dis 2010;20 (Suppl 2):S369-79.
3. Iancu R, Mohapel P, Brundin P, Paul G. Behavioral characterization of a unilateral 6-OHDA-lesion model of Parkinson's disease in mice. Behav Brain Res 2005;162(1):1-10.
4. Dauer W, Przedborski S. Parkinson's Disease: Mechanisms and Models. Neuron 2003;39(6):889-909.
5. Mahmoudi J, Nayebi AM, Reyhani-Rad S, Samini M. Fluoxetine improves the Effect of levodopa on 6-hydroxy dopamine-induced motor impairments in rats. Adv Pharm Bull 2012;2(2):149-55.
6. Maeda T, Kannari K, Huo SH, Arai A, Tomiyama M, Matsunaga M, et al. Increase of the striatal serotonergic fibers after nigrostriatal dopaminergic denervation in adult rats. Int Congr Ser 2003; 1251:211-5.
7. Brown P. Gerfen CR. Plasticity within striatal direct pathway neurons after neonatal dopamine depletion is mediated through a novel functional coupling of serotonin 5-HT2 receptors to the ERK 1/2 Map Kinase pathway. J Comp Neurol 2006;498(3):415-30.
8. Di Matteo V, Pierucci M, Esposito E, Crescimanno G, Benigno A, Di Giovanni G. Serotonin modulation of the basal ganglia circuitry: Therapeutic implication for parkinson's disease and other motor disorders. Prog in Brain Res 2008;172:423-63.
9. Caley CF, Friedman JH. Does fluoxetine exacerbate Parkinson's disease? J Clin. Psychiatry 1992;53:278-82.
10. Steur EN. Increase of Parkinson disability after fluoxetine medication. Neurology 1993;43(1):211-3.
11. Gönül AS, Aksu M. SSRI-induced Parkinsonism may be an early sign of future Parkinson's Disease. J Clin Psychiatry 1999;60(6):410.
12. Paxinos G, Watson C. The rat brain in stereotaxic coordinates. Sydney: Academic Press; 1982.
13. Pires JG, Bonikovski V, Futuro-Neto HA. Acute effects of selective serotonin reuptake inhibitors on neuroleptic-induced catalepsy in mice. Braz J Med Biol Res 2005;38(12):1867-72.
14. Mohajjel Nayebi AA, Sheidaei H. Buspirone improves haloperidol-induced Parkinson disease in mice through 5-HT(1A) recaptors. Daru 2010;18(1):41-5.
15. Navailles S, De Deurwaerdere P. Imbalanced dopaminergic transmission mediated by serotonergic Neurons in L-DOPA-induced dyskinesia. Parkinsons Dis 2012;2012:323686.
16. Nayebi AM, Rad SR, Saberian M, Azimzadeh S, Samini M. Buspirone improves 6-hydroxydopamine-induced catalepsy through stimulation of nigral 5-HT(1A) receptors in rats. Pharmacol Rep 2010;62(2):258-64.
17. Alex KD, Pehek EA. Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission. Pharmacol Ther 2007;113(2):296-320.
18. Dupre KB, Eskow KL, Barnum CJ, Bishop C. Striatal 5-HT1A receptor stimulation reduces D1 receptor-induced dyskinesia and improves movement in the hemiparkinsonian rat. Neuropharmacology 2008;55(8):1321-8.
19. Fox SH, Chuang R, Brotchie JM. Serotonin and parkinson's disease: On movement, mood, and madness. Mov Disord 2009;24(9):1255-66.
20. Eltayb A, Svensson TH, Ahlenius S. Catalepsy induced by the 5-HT(1A) receptor antagonist WAY 100635 in rats pretreated with the selective serotonin reuptake inhibitor citalopram. Eur J Pharmacol 2001;411(3):275-7.
21. van de Vijver DA, Roos RA, Jansen PA, Porsius AJ, de Boer A. Start of a selective serotonin reuptake inhibitor (SSRI) and increase of antiparkinsonian drug treatment in patients on levodopa. Br J Clin Pharmacol 2002;54(2):168-70.
22. Schapira AH. Present and future drug treatment for parkinson's disease. J Neurol Neurosurg Psychiatry 2005;76(11):1472-8.
23. Arya DK. Extrapyramidal symptoms with selective serotonin reuptake inhibitors. Br J Psychiatry 1994;165(6):728-33.